Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Pharvaris (NASDAQ:PHVS) in a research note published on Tuesday morning, Marketbeat.com reports. The firm issued an overweight rating and a $28.00 price target on the stock. Cantor Fitzgerald also issued estimates for Pharvaris’ FY2025 earnings at ($3.31) EPS.

Separately, JMP Securities raised their target price on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Stock Down 3.4 %

Shares of NASDAQ PHVS opened at $17.85 on Tuesday. The business has a fifty day simple moving average of $15.04 and a 200-day simple moving average of $18.06. The company has a market cap of $933.38 million, a price-to-earnings ratio of -6.38 and a beta of -2.84. Pharvaris has a 12 month low of $11.51 and a 12 month high of $25.50.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.06. As a group, sell-side analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. boosted its position in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. FMR LLC raised its stake in shares of Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after purchasing an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP grew its position in Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after acquiring an additional 157,530 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock valued at $1,762,000 after purchasing an additional 76,188 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.